Wells Fargo & Company Verrica Pharmaceuticals Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VRCA
# of Institutions
78Shares Held
14.2MCall Options Held
9.9KPut Options Held
6.5K-
Perceptive Advisors LLC New York, NY7.1MShares$56.4 Million1.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.29MShares$10.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.13MShares$8.98 Million0.0% of portfolio
-
State Street Corp Boston, MA513KShares$4.08 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA455KShares$3.62 Million0.0% of portfolio
About Verrica Pharmaceuticals Inc.
- Ticker VRCA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,094,100
- Market Cap $327M
- Description
- Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...